Revolution Medicines, Inc.

RVMDSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1628171

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$11.6M	$35.4M	$29.4M	$43.0M	$50.0M
Research and Development Expense	$423.1M	$253.1M	$186.9M	$132.3M	$91.8M
Operating Expenses	$498.8M	$293.7M	$217.4M	$153.7M	$104.2M
Operating Income (Loss)	-$487.2M	-$258.3M	-$188.0M	-$110.7M	-$54.1M
Interest Expense	—	—	—	$71.0K	$106.0K
Nonoperating Income (Expense)	$47.3M	$9.2M	$917.0K	$2.2M	$2.1M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$439.9M	-$249.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$2.6B	$2.1B	$811.9M	$738.0M	$567.4M
Assets, Current	$2.3B	$1.9B	$660.2M	$589.8M	$454.1M
Cash and Cash Equivalents, at Carrying Value	$696.1M	$161.4M	$108.5M	$104.3M	$16.7M
Liabilities	$293.1M	$235.5M	$126.7M	$135.4M	$92.7M
Liabilities, Current	$163.9M	$143.9M	$62.0M	$60.4M	$47.2M
Accounts Payable, Current	$54.4M	$61.8M	$21.3M	$14.1M	$12.6M
Stockholders' Equity Attributable to Parent	$685.2M	$602.6M	$474.7M	-$152.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$350.6M	-$224.4M	-$147.2M	-$100.1M	-$49.6M
Net Cash Provided by (Used in) Investing Activities	-$342.6M	-$24.1M	-$142.1M	-$234.2M	-$102.0M
Net Cash Provided by (Used in) Financing Activities	$1.2B	$301.4M	$294.2M	$422.8M	$98.7M
Payments to Acquire Property, Plant, and Equipment	$7.7M	$10.8M	$6.5M	$2.9M	$2.6M
Payments of Dividends	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)